Intellia Therapeutics, Inc. NTLA
Updated: 17 Jun 2026
No signal published yet
We already track Intellia Therapeutics and collect the news. No signal is published yet — follow the company free and we will email you when that changes, or run a quick check now.
Email when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Temporary check — not Firelda's published signal.
General analysis — not personal advice.
Want to follow Intellia Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Intellia Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more
Recent News
On June 14, 2026, Intellia announced positive results from its Phase 3 HAELO clinical trial of lonvo-z for hereditary angioedema, showing an 87% reduction in monthly attack rates. The company also recently resumed clinical trials following the lifting of an FDA hold on two Phase 3 studies. These developments contributed to a 58% increase in the company's stock price year-to-date as of mid-June 2026.
What Firelda Watch includes for Intellia Therapeutics, Inc.
Add the company to your watchlist and get all of this automatically.
- Free: 3 companies on your watchlist
- Change history and monitoring for every company you follow
- Sunday weekly brief — a short weekly roundup
- Watch/Ultra: same-day email when something material happens
Want to see what a finished analysis looks like?
View a sample analysis
Want to follow Intellia Therapeutics, Inc.? Create a free account — 3 companies, change history, weekly brief, and email when the picture changes.
Follow Intellia Therapeutics free Follow freeEmail when we publish a signal or something material happens · Sunday weekly brief
No card · No time limit on free tier · Upgrade when you need more